Stocktoria
FATE THERAPEUTICS INC FATE
FATE THERAPEUTICS INC (FATE) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $6.6M at a -2051.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.541 |
| Retained earnings / assets | -4.811 |
| EBIT / assets | -0.463 |
| Equity / liabilities | 1.854 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | 1/9 | -13.3 | — | -51.2% |
| DBVT | DBV Technologies S.A. | 3/9 | -2.63 | — | — |
| OCGN | Ocugen, Inc. | 2/9 | — | — | — |
| CGON | CG Oncology, Inc. | 2/9 | — | — | — |
| CRIS | CURIS INC | 2/9 | — | — | -13.4% |
| TSHA | Taysha Gene Therapies, Inc. | 4/9 | -0.53 | — | — |
| CRSP | CRISPR Therapeutics AG | 1/9 | 6.42 | — | -90.6% |
About FATE THERAPEUTICS INC
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FAQ
Is FATE financially healthy?
FATE THERAPEUTICS INC's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does FATE pay a dividend?
No, FATE THERAPEUTICS INC does not currently pay a dividend.
How profitable is FATE?
In FY2025, FATE THERAPEUTICS INC had a net margin of -2051.1% and a return on equity of -65.8%.
What is the analyst price target for FATE?
The average Wall-Street price target for FATE THERAPEUTICS INC is $5.41, about 98.9% above the recent price, from 9 analysts (consensus: buy).
Is FATE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on FATE THERAPEUTICS INC: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.